SUPERNUS PHARMACEUTICALS, INC. SUPN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, SUPERNUS PHARMACEUTICALS, INC. reported revenue across 1 business segments; the largest, Reportable Segment, was $719M, 100.0% of the filed sum (+8.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$719M100.0%+8.6% yoy
Members sum to the consolidated $719M for this period.
- Product$627Mshare n/a-1.8% yoy
- Qelbree$305Mshare n/a+26.3% yoy
- GOCOVRI$147Mshare n/a+12.2% yoy
- Collaboration Revenue$53Mshare n/ano prior
- APOKYN$47.8Mshare n/a-35.4% yoy
- Trokendi Xr$42.4Mshare n/a-32.9% yoy
- Oxtellar XR$40.7Mshare n/a-59.1% yoy
- Royalty License And Other Revenue$39.4Mshare n/a+63.4% yoy
- +2 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Reportable Segment$208M100.0%+38.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.